Citadel Advisors’s Global X China Biotech Innovation ETF CHB Stock Holding History

Citadel Advisors’s Portfolio CHB Stock Details CHB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24,314	Closed	-$197K	–	15796
2023 Q4	$197K	Buy	24,314 +84	+0.3%	+$669	﹤0.01%	9986
2023 Q3	$183K	Sell	24,230 -713	-3%	-$5.35K	﹤0.01%	10056
2023 Q2	$192K	Hold	24,943	–	–	﹤0.01%	9962
2023 Q1	$225K	Buy	+24,943	New	+$251K	﹤0.01%	9966

Citadel Advisors's CHB Position: Q1 2024 in Review

Citadel Advisors sold out of Global X China Biotech Innovation ETF (CHB) in Q1 2024, closing a stake of 24,314 shares — an estimated $197K sold.

Citadel Advisors first reported a position in CHB in Q1 2023 and held it in 4 quarters. The position peaked at $225K in Q1 2023. 0 funds tracked by Wall St. Rank hold CHB as of Q1 2024.

Citadel Advisors reported no remaining Global X China Biotech Innovation ETF position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 24,314 Global X China Biotech Innovation ETF shares in Q1 2024, an estimated $197K.
Citadel Advisors first reported a position in Global X China Biotech Innovation ETF in Q1 2023 and held it in 4 quarters.
Citadel Advisors's Global X China Biotech Innovation ETF position peaked at $225K in Q1 2023.
0 funds tracked by Wall St. Rank held Global X China Biotech Innovation ETF as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.